Ülseratif kolit hastalığı kemik mineral yoğunluğunu etkiler mi?

Giriş: İnflamatuvar bağırsak hastalığında kemik mineral kaybı (KMK) normal sağlıklı topluma göre daha fazla görülmektedir (%32-77). Özellikle Crohn hastalığında KMK daha belirgin olmasına rağmen Ülseratif Kolit (ÜK) hastalığında çelişkili sonuçlar vardır. Özellikle de kortikosteroid kullanan hastalarda KMK daha fazla olabilmekte ve erken yaşlarda ortaya çıkabilmektedir. Amaç: Ülseratif Kolitli hastalarda hastalık yaşı, hastalık tutulum yeri, hastalık aktivitesi, cinsiyet ve steroid kullanımı ile osteopeni ve osteoporoz arasında ilişki olup olmadığını tespit etmeyi amaçladık. Materyel ve Metod: Çalışmamıza Ocak 2014 ile Şubat 2018 tarihleri arasında Manisa Celal Bayar Üniversitesi Tıp Fakültesi Gastroenteroloji Kliniğine başvuran ve tarafımızca ÜK tanısı konup takip edilen onbeşi ’i erkek, yirmi biri’i kadın toplam 36 hasta alındı. Bu hastaların Kemik mineral yoğunluğu (KMY) DEXA cihazı ile ölçüldü, retrospektif olarak kayıtları incelendi. Hastalık tanısı, klinik bulgular, kolonoskopi ve histopatoloji ile konuldu. Tüm hastalara DEXA DPX-PRO (GE-LUNAR DPX-NT) ile APspine (vertebra) ve femur boynu kemik mineral dansitometre ölçümü yapıldı. T skor değerleri >-1 normal, -1>T>-2,5 osteopeni, T<-2,5 değerleri osteoporoz olarak değerlendirildi. Hastalar; klinik aktivite, tutulum yeri, cinsiyet, steroid kullanımı, hastalık yaşı açısından değerlendirildi. Tüm hastaların KMY ölçülerek bu parametreler ile ilişkileri araştırıldı. Bulgular: Çalışmaya alınan erkek hastaların yaş ortalamaları 46,66, kadın hastaların yaş ortalamaları 46,52 idi. Erkeklerin yedi’sinde (%46,6), kadınların on’unda (%47,6) osteopeni tespit edildi. Ayrıca bir erkek hastada (%3) ve 2 kadın hastada (%9,5) osteoporoz saptandı. Hiçbir hastada kemik kırığı yoktu. Osteopoz tanısı konulan 3 hastanın bir’inde (%33) Pankolit, iki’sinde (%66) proktitis mevcuttu. Osteopeni tespit edilen 17 hastanın altısında (%35,3) pankolit, onunda (%58,8) proktit mevcuttu. Aktif ÜK olan otuzüç hastanın yirmisinde (%60,6) KMK (17’si osteopeni, 3’ü osteoporoz) tespit edildi, 13’ünde (%39,4) ise KMK yoktu. İnaktif koliti olan üç hastanın birinde KMK tespit edildi. Sonuç: Kadınlarda aktif ÜK de KMK daha fazlaydı. Ayrıca Aktif ÜK olan hastaların %55,55’sında kemik mineral bozukluğu mevcut olup hastalık aktivitesi ile KMK arasında pozitif ilişki tespit edilmedi. Kolon tutulum yeri ile KMK arasında fark yoktu. Ayrıca Kortikosteroid kullanımı ile KMK arasında ise pozitif bir ilişki bulunamadı.Aim: The aim of this study was to determine the frequency of osteopenia and osteoporosis in ulcerative colitis (UC) patients and the relationship between disease age, disease incidence, disease activity, sex and steroid use, osteopenia and osteoporosis. Materials and Methods: 36 patients (15 men and 21 women with ulcerative colitis) who were admitted to the Gastroenterology Clinic of Manisa Celal Bayar University Faculty of Medicine between January 2014 and February 2018 and whose bone mineral density was measured (DEXA) were included in the study. retrospectively reviewed their records.Patients. Clinical activity was assessed in terms of location, sex, steroid use, and age of the disease. Bone mineral density of all patients was measured and their relationship with these parameters was investigated. Findings: A total of 36 patients with ulcerative colitis who were measured bone mineral density were included in the study. 15 of these patients were male (mean age 46,66) and 21 were female (mean age 46,52). Osteopenia was detected in 7 (46,6%) of the males and 10 (47,6%) of the females. In addition, osteoporosis was detected in 1 male patient (3%) and 2 female patients (9,5%) and no bone fracture was observed in any patient.Bone mineral deficiency (17% osteopenia, 3 osteoporosis) was detected in 20 of 33 patients with active ulcerative colitis (60,6%) and bone mineral loss (BMD) was absent in 13 patients (39,4%). bone mineral loss was detected in one, not in two. Conclusion: Female ulcerative colitis bone mineral loss was greater in women. In addition, bone mineral deficiency was found in 55,55% of patients with active ulcerative colitis and there wasn’t a positive relationship between disease activity and BMD. There was also no positive correlation between corticosteroid use and BMD

The Effects of Medicinal Plants on Cancer Cell Lines and Efficacy of Experimental Animal Model

The use of medicinal plants as an alternative treatment is a historical process and has been known for a long time so that classical treatment can be more effective in wound and cancer treatment. The purpose of this study was to investigate the effects of plant extracts used for therapeutic purposes in cancer cell lines in vitro wound model and in vivo experimental animal model in order to obtain this information. The plants, olive oil (Oleocanthal), mistletoe (Viscum album), Common Centaury (Centaurium erythraea), Momordica charantia, Inula viscosa, Citrus aurantium, Thyme oil (Thymus vulgaris) and algae (Jania longifurca), were used. MCF-7, MB-MDA-231, 67NR and 4T1 for breast, NB2a for neuron, L929 for fibroblast and normal somatic mesenchymal stem cell for comparison were selected for in vitro wound models. As an in vivo breast cancer model, female Balb/c mice were injected with 4T1 cells and skin wound healing in rats was investigated. The effects of medicinal plants were evaluated using MTT assay for viability and proliferation, immunocytochemistry staining NOS for oxidative stress and TGFbeta1 for wound healing. It was found that plant extracts reduced antioxidative damage and inhibited apoptosis. It was observed that oxidative stress and apoptosis were increased in cancer cells, but less effective in invasive cell lines. In vivo experiments showed that wound healing was accelerated and that these rates were achieved with antioxidative and antiapoptotic effects. It has been concluded that medicinal plants are beneficial for treatment of difficult diseases in which patient quality of life is very effective and they should be used as scientific-based medical applications

Molecular analyses of ADAMTS-1, -4, -5, and IL-17 a cytokine relationship in patients with ulcerative colitis

Abstract Background Ulcerative colitis (UC) is a chronic inflammatory bowel disease that develops due to the impaired immune response in genetically susceptible individuals, and its etiopathogenesis is not fully elucidated. IL-17 A is a cytokine that is produced by a type of immune cell called Th17 cells and is involved in the immune response and inflammation. On the other hand, ADAMTS-1, -4, and − 5 are enzymes that are involved in the breakdown of extracellular matrix proteins, including proteoglycans, which are important components of the intestinal wall. This study aimed to evaluate the relationship between interleukin 17 (IL-17 A) cytokine, which plays a role in the pathogenesis of ulcerative colitis, and the inflammation-controlled a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-1, -4, and − 5 protein members. Methods Bowel tissue samples and blood serum from 51 patients with UC and 51 healthy controls were included in this study. mRNA expression levels of the ADAMTS-1, -4, -5, and IL-17 A were analyzed by RT-qPCR, and immunohistochemical analyses were performed to evaluate ADAMTS-1, -4, -5, and IL-17 A proteins in tissue samples. In addition, ELISA analysis determined serum levels of the ADAMTS-1, -4, -5, and IL-17 A. Results RT-qPCR results reveal that the expression of ADAMTS-1, -4, -5, and IL-17 A genes in the UC tissue samples were significantly high according to the control tissue samples. Also, ADAMTS-1, -4, -5, and IL-17 A proteins revealed enhanced expression pattern UC groups according to the control. Also, ADAMTS-1, -4, -5, and IL-17 A protein showed cytoplasmic localization patterns in both control and UC groups. The serum levels of ADAMTS-1,-5, and IL-17 A were significantly higher in UC samples than in the control group. Conclusions We observed a positive correlation between the ADAMTS-1, -5 and IL17A cytokine expression in UC samples. These results provide a new understanding of controlling crucial ADAMTS family protein members by IL-17 A cytokines with UC